Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Slides:



Advertisements
Similar presentations
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Advertisements

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
A) Pulmonary veno-occlusive disease (PVOD) with partial thrombotic occlusion of the lumen of a medium-sized vein (haematoxylin and eosin stain, 200× original.
Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
The management options for chronic thromboembolic pulmonary hypertension (CTEPH) target different pathogenic manifestations in different parts of the pulmonary.
Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.
Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.
Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.
Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)
Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.
Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.
Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)
Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;
Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.
3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).
Evaluation of cognitive performance based on the ability to copy a simple drawing. Evaluation of cognitive performance based on the ability to copy a simple.
Profile of Pseudomonas aeruginosa resistance by country and antibiotic
Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.
The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.
Elastic staining of paraffin-embedded lung tissue.
The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.
Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.
Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,
Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;
Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.
Incidence of chronic obstructive pulmonary disease according to the history of chronic cough/phlegm. Incidence of chronic obstructive pulmonary disease.
Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.
A pump function graph demonstrating mean right ventricular pressure as a function of stroke volume (SV). A pump function graph demonstrating mean right.
Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.
Haemodynamic response to exercise in a) normal subjects and b) Fontan patients. Haemodynamic response to exercise in a) normal subjects and b) Fontan patients.
The minute ventilation (V′E)/carbon dioxide production (V′CO2) relationship slope in a patient with pulmonary arterial hypertension and preserved physiological.
Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,
Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.
Conceptual model of the ageing Fontan circulation
Cardiac magnetic resonance imaging of the heart in a patient with pulmonary arterial hypertension. a) Short axis image. #: dilated right ventricle; ¶:
Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.
Kaplan–Meier survival curves for baseline cardiac magnetic resonance imaging variables according to the median value in patients with pulmonary hypertension.
Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.
A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.
A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.
Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.
Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.
Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s
A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.
Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.
Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.
Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.
Lung histology from a case of pulmonary tumour thrombotic microangiopathy related to severe pulmonary hypertension. a) Post mortem section showing occlusion.
Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.
Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )
Clinical findings in patients with chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.
Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.
Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.
Kaplan–Meier survival plot of 101 cases of severe (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3) and very severe (GOLD stage 4)
24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.
Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.
A) Chest radiograph of a 37-year-old male mountaineer with high-altitude pulmonary oedema (HAPE) showing a patchy to confluent distribution of oedema,
Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.
Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.
Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.
Pulmonary arterial imaging before and after percutaneous balloon pulmonary angioplasty (BPA). a) Pre-procedure pulmonary angiogram demonstrating an intra-arterial.
Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.
Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.
Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.
Presentation transcript:

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small pulmonary artery. Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small pulmonary artery. Multiple slit-like vascular spaces are all that remain of the original lumen (Haematoxylin-eosin). Reproduced from [19] with permission from the publisher. Andrew Peacock Eur Respir Rev 2013;22:20-25 ©2013 by European Respiratory Society